Fig. 1a



BeWo, 5x10E4 cells/well, 3D
normalized RLU
17870
15870
13870
11870
9870
7870
5870
3870
1870
-130
Minimal Medium
CSF-1
mIgG1
mIgG2A
Ab SC-2-4A5
Mab 2E10
Mab 2F11

Fig. 1b



BeWo, 5x10E4 cells/well, 3D
RLU
15870
13870
11870
9870
7870
5870
3870
1870
-130
Minimal Medium
CSF-1
mIgG1
mIgG2A
Ab SC-2-4A5
Mab 2E10
Mab 2F11
Mab 2H7
Mab 1G10

Fig. 2a



Mab 3291
sc2-4A5
Mab 2F11 / Mab 2E10 / m<CCR5>Pz03.1C5
RU
1200
1000
800
600
400
200
0
-200
0
200
400
600
800
1000
Time
s

Fig. 2b



Mab 3291
sc2-4A5
Mab 2F11
Mab 2E10
m<CCR5>Pz03.1C5
RU
800
700
600
500
400
300
200
100
0
-100
0
200
400
600
800
1000
Time
s

Fig. 2c



Mab 1G10/ Mab 2H7/
hMab 2F11-e7/
m<CCR5>Pz03.1C5
RU
300
250
200
150
100
50
0
-50
-100
Response (0 = baseline)
0
100
200
300
400
500
600
700
800
900
1000
s
Time

Fig. 2d



Mab 1G10
hMab 2F11-e7
Mab 2H7
m<CCR5>Pz03.1C5
RU
3000
2500
2000
1500
1000
500
0
-500
Response (0 = baseline)
0
100
200
300
400
500
600
700
800
900
1000
s
Time

Fig. 2e



CXIIG6
MAB 3291
ab10676
1.2.SM
m<CCR5>Pz03.1C5
RU
2500
2000
1500
1000
500
0
-500
Response (0 = baseline)
0
200
400
600
800
1000
Time
s

Fig. 2f



CXIIG6
MAB 3291
1.2.SM
ab10676
m<CCR5>Pz03.1C5
RU
1600
1100
600
100
-400
Response (0 = baseline)
0
200
400
600
800
1000
Time
s

Fig. 3a



CSF-1 ELISA - Cyno Plasma Batch 1
(0.1 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 3b



CSF-1 ELISA - Cyno Plasma Batch 1
(1 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 3c



CSF-1 ELISA - Cyno Plasma Batch 1
(10 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 3d



CSF-1 ELISA - Cyno Plasma Batch 1
(100 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 4



Tumor Volume [mm³]; Median with IQR
0
200
400
600
800
1000
1200
1400
Days after cell inoculation [d]
48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96 98 100 102 104 106
vehicle
chimeric <CSF-1R> Mab 2F11; 20mg/kg i.p.
<CSF-1R> 1.2.SM; 20mg/kg i.p.

Fig. 5a



CSF-1
GM-CSF
120%
100%
80%
60%
40%
20%
0%
% cell viability
0,0001
0,0010
0,0100
0,1000
1,0000
10,0000
conc. of hMab 2F11-e7 [µg/ml]

Fig. 5a




Fig. 6a



CSF1R_Pz_MC38_002
Mean tumor volume [mm³] +/- SEM
Days after cell inoculation [d]
treatment with
IgG1 Mouse
<mouse CSF1R> antibody
IL-2
Combi <mouse CSF1R> antibody + IL-2
0
500
1000
1500
2000
2500
3000
5
7
9
11
13
15
17
19
21
23

Fig. 6b



CSF1R_Pz_MC38_002
Mean tumor volume [mm³] +/- SEM
Days after cell inoculation [d]
treatment with
IgG1 Mouse
<mouse CSF1R> antibody
FOLFIRI
Combi <mouse CSF1R> antibody + FOLFIRI
0
500
1000
1500
2000
2500
3000
5
7
9
11
13
15
17
19
21
23

Fig. 6c




CSF1R_Pz_MC38_002
treatment with
IgG1 Mouse
<mouse CSF1R> antibody
oxaliplatin
Combi <mouse CSF1R> antibody + oxaliplatin
Mean tumor volume [mm³] +/- SEM
Days after cell inoculation [d]
0
500
1000
1500
2000
2500
3000
5
7
9
11
13
15
17
19
21
23

Fig. 7


Tumor Volume [mm3] Mean +/-SEM
0
200
400
600
800
1000
1200
1400
1600
7
10
14
17
Study Day
IgG control
CSF1R mAb
CD40 mAb (FGK45)
CSF1R mAb + CD40 mAb (FGK45)